IP Verse

Bülle Dr., Jan competitive analysis

Explore patent oppositions filed by Bülle Dr., Jan against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Aug 27, 2026

Patent Number	Title	Applicant	Opposition Date
EP4188389	Methods Of Treating Chronic Kidney Disease With Dapagliflozin	ASTRAZENECA	Jun 9, 2026
EP4321157	New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)	NOVARTIS	Jul 22, 2025
EP3565419	Crystallisable D-Allulose Syrups	ROQUETTE FRRES	Feb 7, 2025
EP2395968	Pharmaceutical Composition Comprising Glucopyranosyl Diphenylmethane Derivatives, Pharmaceutical Dosage Form Thereof, Process For Their Preparation And Uses Thereof For Improved Glycemic Control In A Patient	BOEHRINGER INGELHEIM	Oct 15, 2024
EP3626270	New Use	NOVARTIS	Jul 10, 2024
EP3532481	Method For Producing Allulose Crystals	TATE & LYLE INGREDIENTS AMERICAS	Mar 14, 2024
EP3810201	Gip/Glp1 Agonist Compositions	ELI LILLY	Mar 7, 2024
EP3294283	Sacubitril-Valsartan Dosage Regimen For Treating Heart Failure	NOVARTIS	Dec 8, 2023
EP3663375	Structural Adhesive Compositions	PPG INDUSTRIES OHIO	Oct 18, 2023
EP3067043	Pharmaceutical Compositions Based On Superstructures Of Angiotensin Receptor Antagonist/Blocker (Arb) And Neutral Endopeptidase (Nep) Inhibitor	NOVARTIS	Aug 28, 2023

Discover the latest PTAB cases involving Bülle Dr., Jan, highlighting their recent legal challenges and patent disputes.

IP litigation analysis comparing Bülle Dr., Jan with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
BÜLLE DR., JAN	20	-	-	-
ALFRED E TIEFENBACHER	50	5	-	-
ASTELLAS PHARMA	-	35	-	1
NOVARTIS	6	467	-	21